A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Temozolomide in Patients With Recurrent or Progressive Glioblastoma Multiforme (GBM)
Study Details
Study Description
Brief Summary
This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
In Phase 1, patients with recurrent or progressive glioblastoma multiforme who failed with the standard of care will be enrolled at each dose level of BEY1107 in combination with Temozolomide.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: BEY1107 + Temozolomide Administer BEY1107 in combination with Temozolomide, 4-weeks as 1 cycle. |
Drug: BEY1107
Administer twice daily, PO, 4-week continuous dose.
Combination Product: Temozolomide
Administer once daily, PO, 5-day continuous dose, followed by 23-day rest period.
|
Outcome Measures
Primary Outcome Measures
- Maximum Tolerated Dose(MTD) [From baseline up to disease progression, approximately 4 weeks]
MTD will be assessed based on dose-limiting toxicity(DLT) assessment
- Recommended Phase II Dose (RP2D) assessed by investigator following administration of BEY1107 in combination with Temozolomide in Phase I. [From baseline up to disease progression, approximately 48 weeks]
RP2D will be assessed based on MTD.
Secondary Outcome Measures
- Disease control rate(DCR) [From baseline up to disease progression, approximately 48 weeks]
DCR is defined as the proportion of participants who achieved a confirmed best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD)
- Progression-free survival(PFS) rate at 6 months [From baseline up to 6 months]
PFS is defined as the time from the start of study treatment to the date of the first documentation of objective progressive disease(PD) or death due to any cause, whichever is earlier
- Pharmacokinetic(PK) of maximum serum Concentration (Cmax) [From baseline up to 4 weeks post-dose]
Plasma concentrations at each time point and PK parameters Cmax of BEY1107 will be assessed in the PK sampling cohort
- Pharmacokinetic of Time to Reach Maximum Serum Concentration (Tmax) [From baseline up to 4 weeks post-dose]
Plasma concentrations at each time point and PK parameters Tmax of BEY1107 will be assessed in the PK sampling cohort
- Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) [From baseline up to 4 weeks post-dose]
Plasma concentrations at each time point and PK parameters AUC last of BEY1107 will be assessed in the PK sampling cohort
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult males and females aged over 19 years or older at the time of Informed Consent.
-
Diagnosed with GBM according to the World Health Organization(WHO) criteria.
-
Subjects with progression or recurrence, with no response to the initial standard of care after being confirmed as GBM on histopathology.
-
Subjects with 1 or more lesions that are measurable or evaluable according to the Response Assessment in Neuro-Oncology(RANO) criteria.
-
Subjects with European Cooperative Oncology Group(ECOG) performance status 0 or 1.
-
For Subjects using corticosteroids, those who do not need escalation within at least 2 weeks prior to administration of Investigational Product(IP) and on a stable dose.
-
Women of childbearing potential who are not surgically sterile must consent to practice acceptable contraception until 6 months after the end of IP administration and also have the evidence of not being fertile.
8 Non-vasectomized men who consent to use an acceptable contraception by one-self and the partner until 3 months after the end of IP administration.
- Subjects who are fully informed of this trial, voluntarily decide to participate in the trial and provide written consent to comply with requirements for the trial.
Exclusion Criteria:
-
Patients with a history of chemotherapy for treatment of recurrent glioblastoma multiforme after the initial standard of care as of screening.
-
Subjects who have not recovered from the toxicity of the prior anticancer therapy.
-
Subjects who have past history of major gastrointestinal surgery making oral drug administration impossible or possibly affecting absorption of IP.
-
Subjects who had a major surgery requiring general anesthesia within 4 weeks of screening.
-
Subjects with a history of other malignancy except adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ, papillary thyroid cancer or early gastric cancer.
-
Subjects with a genetic problem(eg. Galactose intolerance).
-
Subjects with hypersensitivity to the ingredient(s) or excipient(s) of the investigational product (BEY1107) or temozolomide.
-
Subjects with hypersensitivity to dacarbazine (DTIC).
-
Subjects who have the cardiovascular disease as of screening.
-
Active hepatitis B, C or HIV positive.
-
Patients with acute or severe infection.
-
Subjects who take a Rifampin, Phenytoin and azole class antifungal drugs in combination.
-
Subjects who had been administered other IP within 4 weeks prior to screening.
-
Patients with inadequate bone marrow, kidney and liver function.
-
Pregnant women, breastfeeding women, or positive findings on the pregnancy test at screening.
-
Subjects with life expectancy of less than 12 weeks by the investigator.
-
Subjects determined by the investigator to be ineligible for participation in this trial.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Seoul National University Hospital | Seoul | Korea, Republic of |
Sponsors and Collaborators
- BeyondBio Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BEY-2021-02